within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AD02_Lomustine;

model Lomustine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 1,
    Cl = 5.95e-05,
    adminDuration = 600,
    adminMass = 130 / 1000000,
    adminCount = 1,
    Vd = 0.086,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0023333333333333335,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lomustine</td></tr><tr><td>ATC code:</td><td>L01AD02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>130</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>86</td><td>L</td></tr>
    <tr><td>clearance:</td><td>51</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lomustine is an alkylating nitrosourea compound used primarily as a chemotherapeutic agent in the treatment of Hodgkin's lymphoma, brain tumors (especially gliomas), and certain other cancers. It is approved for human use and is typically used where other regimens have failed or for recurrent disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data in adult cancer patients after a single oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01AD02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lomustine;
